This page is part of our 2025 average annual return archive: it shows the IMDX stock yearly return for calendar year 2025. This metric helps investors evaluate and compare performance among different stocks, over time.
Average annual return should be reviewed alongside overall market trends, and company fundamentals like earnings and revenue. As the saying goes on Wall St., past performance from 2025 does not guarantee future similar returns.
| IMDX Stock Yearly Return 2025 Table | ||||||||||||||||||||||||||||||
IMDX average annual return is presented with the assumption of reinvestments of any dividends on ex-date. |
| Average Annual Return Benchmarks |
|
Compare IMDX average annual return versus benchmarks: S&P Average Annual Return Dow Average Annual Return Nasdaq 100 Average Annual Return Russell 2000 Average Annual Return Gold Average Annual Return 10 Year Treasury Average Annual Return |
| IMDX Share Performance |
| IMDX Stock Yearly Return 2025 Chart | |||
Also see: • IMDX YTD return • IMDX average annual return 10 years | |||
| About Insight Molecular Diagnostics Inc |
| Oncocyte Corporation is a precision diagnostics company. Co. is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. Co.'s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. The IMDX stock yearly return is shown above.
The yearly return on the IMDX stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2025 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon. One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the IMDX annual return calculation with any dividends reinvested as applicable (on ex-dates). |
| IMDX Current Stock Quote |
 Free IMDX Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Don't Forget Dividends in Annual Return! | |
|
| Yearly Return Peers |
| Insight Molecular Diagnostics (IMDX) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:
IMMX Average Annual Return |
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 7.6%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 7.6%.
Video: Don't Forget Dividends in Average Annual Return!